ArticleInternational journal for parasitology. Drugs and drug resistance2019
Development of unstable resistance to diminazene aceturate in Babesia bovis.
Article in International journal for parasitology. Drugs and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Exploring the landscape of Babesia bovis vaccines: progress, challenges, and opportunities.Parasites & vectors · 2023Pooled it
- Identification of Small-Molecule Inhibitors ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Tafenoquine: A Breakthrough Option for Babesiosis Treatment.Tropical medicine and infectious disease · 2026Article
- Natural products against Babesiosis: active compounds, molecular mechanisms, application limitations and translational development.Frontiers in cellular and infection microbiology · 2026Review
- Minor groove binding of imidocarb dipropionate to calf thymus DNA: insights from multispectral, thermodynamic, and molecular docking approaches.RSC advances · 2025Article
- Risk Factors Associated with Hemoparasites in Dual-Purpose Cattle of Colombia.Pathogens (Basel, Switzerland) · 2025Article
- Exploring novel inhibitors for Babesia bigemina lactate dehydrogenase: a computational structural biology perspective.Parasitology research · 2025Article
- Comparative chemical genomics inProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Unrevealing the therapeutic potential of artesunate against emerging zoonoticFrontiers in veterinary science · 2024Article
- Article
- Immunization of Cattle With Recombinant Structural Ectodomains I and II ofFrontiers in veterinary science · 2022Article
- Review
- EstablishingPathogens (Basel, Switzerland) · 2021Article
- Structural and immunological characterization of an epitope within the PAN motif of ectodomain I inPeerJ · 2021Article
- Humoral and Cell-Mediated Immune Response Validation in Calves after a Live Attenuated Vaccine ofPathogens (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diminazene aceturate (DA) is commonly used in the treatment of bovine babesiosis caused by Babesia bovis. In this study, we attempted to develop resistance in B. bovis in vitro to DA and clofazimine (CF, a novel antibabesial agent) using short- and long-term drug pressures. In the short term, we found that 6.7 ± 2 (0.54 ± 0.16 μM)-, 12.9 ± 8.6 (1.05 ± 0.7 μM)-, and 14 ± 5.9 (1.14 ± 0.48 μM)-fold increases in the half-maximal inhibitory concentration (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.